Eli Lilly CEO previews the next generation of weight-loss drugs

Eli Lilly chair and CEO Dave Ricks discusses the company's expansion and 150th year in business on ‘Claman's Power Players.' #fox #foxbusiness #media #breakingnews #us #usa #new #news #breaking #clamanspowerplayers #lizclaman #claman #elililly #davericks #ricks #weightloss #weightlossdrugs #obesity #obesitytreatment #glp1 #pharmaceuticals #pharma #pharmaceuticalindustry #healthcare #healthcareinnovation #drugdevelopment #artificialintelligence #ai #aitechnology #biotech #biotechnology #medicalresearch #medicine #business #businessnews #innovation #technology #drugdiscovery #healthtech #ceo #corporateexpansion

Fox Business • 9 hours ago

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FR α expression levels Clinical activity with Sofe-M was maintained even in patients with prior PARP inhibitor exposure, patients who typically experience poor outcomes with platinum-based chemotherapy Sofe-M is currently being studied in both platinum-sensitive and platinum-resistant ovarian cancer in multiple Phase 3 studies as part of the FRAmework-01 master protocol INDIANAPOLIS, Oct. 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its investigational folate receptor alpha (FRα) antibody-drug conjugate (ADC) sofetabart mipitecan (Sofe-M) plus bevacizumab achieved a confirmed objective response rate (cORR) of 79% and a disease control rate (DCR) of 100% in patients with platinum-sensitive ovarian cancer (PSOC). A cORR of 79% or higher was seen in both poly (ADP-ribose) polymerase inhibitor (PARPi)-treated and PARPi-naïve patients.

PRNewsWire • 7 hours ago

Eli Lilly's Fast Growth Hasn't Slowed Its Progress As Sustainability Leader

Eli Lilly's commitment to philanthropy, coupled with a dedication to environmental progress, make it a sustainability leader.

Investors Business Daily • Oct 23, 2026

GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says

The ​combined China-India-Brazil market for weight-loss drugs could grow to $22 billion by 2035 from $6.6 ‌billion currently, J.P. Morgan estimated, as improving affordability and broader access drive adoption in largely untapped patient populations.

Reuters • Oct 23, 2026

2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)

Axsome Therapeutics should expand its approved lineup while not facing the threat of generic competition through 2036. Eli Lilly is a leader in its core market and could diversify its lineup over the long run.

The Motley Fool • 18 hours ago

Eli Lilly (LLY) Price Forecast: Breakout Strengthens Ahead of Earnings

Eli Lilly reaches a record high ahead of earnings, strengthening its bullish trend as technical signals point toward potential upside targets between $1,384 and $1,406.

FXEmpire • Oct 22, 2026

Earnings Preview: Eli Lilly (LLY) Q3 Earnings Expected to Decline

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 22, 2026

Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020

First Lilly site to produce both active pharmaceutical ingredients and finished medicines in a fully integrated facility Site will create 650 high-wage jobs INDIANAPOLIS, Oct. 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) broke ground today on a new $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County, one of 10 new U.S. manufacturing sites announced since 2020 and one of five among them that will produce active pharmaceutical ingredients (API). As part of the company's more than $50 billion push to expand medicine production in the U.S., the Richmond site will be Lilly's first to produce both API and finished medicines in a fully integrated facility, with dedicated API capacity for bioconjugate and large-molecule medicines.

PRNewsWire • Oct 22, 2026

Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?

Bristol Myers Squibb (BMY -0.91%) primarily generates its revenue by developing and selling prescription therapeutic medications for oncology and cardiovascular health worldwide.

The Motley Fool • Oct 22, 2026

Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?

Amgen maintains a diverse portfolio focused on oncology, rare diseases, and inflammation while providing steady cash flow generation. Eli Lilly & Co. continues to see explosive growth driven by its dominant position in the cardiometabolic and incretin drug markets.

The Motley Fool • Oct 22, 2026